Introduction
Invasive aspergillosis (IA) is a major cause of morbidity and mortality in patients who are severely immunocompromised, e.g., those with prolonged neutropenia and/or undergoing hematopoietic stem cell transplantation [1] . However, autopsy studies have revealed that Aspergillus infections are among the most commonly missed diagnoses [2, 3] , not only in hematologic patients, but also in those with chronic obstructive pulmonary disease (COPD), liver cirrhosis, or receiving prolonged courses of steroids [4] .
Establishing a diagnosis of IA at an early stage of the disease is necessary for successful treatment, but challenging in critically ill non-neutropenic patients. Clinical signs are frequently lacking in these individuals, fungal cultures provide limited information, and radiological signs are ascites and encephalopathy. His medical history was remarkable for chronic obstructive pulmonary disease (COPD) and diabetes mellitus, as well as receiving steroids by inhalation (fl uticasone). After an initial improvement of his general condition, the patient on day 6 became increasingly dyspnoeic, febrile (38.9 ° C) and arterial blood gases revealed acute respiratory failure (PaO2 51 mmHg). The radiographic evaluation showed bilateral pulmonary infi ltrates. Laboratory studies indicated a total leucocyte count of 11,000/mm 3 (92% of neutrophils), with raised erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels. Examination of computed tomography (CT) scans revealed multiple segmental areas of consolidation and nodules. Tests for Legionella antigenuria were negative. All blood cultures were negative, while a sputum sample yielded Aspergillus fumigatus in culture. The patient remained febrile after six days of empiric antibiotic therapy with imipenem plus linezolid and therefore a galactomannan (GM) antigen test (Platelia Aspergillus , Manufacturer Bio-Rad laboratories) was conducted that was positive in sputum (1.2 Optic Index [OI], cut-off Ͼ 0.48) but negative in serum (0.25 OI, cut-off Ͼ 0.48). Bronchoscopy with bronchoalveolar lavage (BAL) was conducted with positive results in the BAL GM (1.97 OI, cut-off Ͼ 0.52). Despite intravenous voriconazole therapy (loading dose 400 mg two times on day 1, maintenance dose 200 mg twice daily) the patient developed multiple organ failure and died 3 weeks after admission (at the third day of voriconazole treatment). The autopsy study confi rmed the presence of septate hyphae in the lung tissues which yielded A. fumigatus in culture .
Case report 2
A 51-year-old man was admitted to our hospital for acute alcoholic hepatitis, dyspnea and fever. He was homeless, a smoker, and with a history of frequent admissions for acute alcoholic intoxication. The arterial blood gases revealed a respiratory failure (PaO2 51 mmHg), and a chest radiograph showed a segmental area of consolidation. The patient was treated with meropenem plus levofl oxacin with defervescence of fever and improvement of the respiratory function. Blood cultures were negative, while a sputum culture yielded an isolate of Aspergillus fl avus . After the clinical resolution of pneumonia the patient was treated for alcoholic hepatitis with i.v. methylprednisolone (40 mg/d). However, on day 10 of steroid therapy the patient developed fever again and acute respiratory failure (arterial PaO2 44 mmHg) with a total leucocyte count of 25,000/mm 3 (95% of neutrophils) and thrombocytopenia (55,000/mm 3 ). Chest radiograph showed interstitial lung infi ltrates and multiple nodules, and a CT scan indicated multiple areas of consolidation with nodules and pleural effusions. Bronchoscopy with BAL was performed before the initiation of an empirical antibiotic therapy with meropenem, vancomycin, and levofl oxacin. The GM detection was positive both in BAL (1.6 OI, cut-off Ͼ 0.51) and sputum (1.2 OI, cut-off Ͼ 0.51), but negative in the serum (0.33 OI, cut-off Ͼ 0.51). Intravenous liposomal amphotericin B (L-AMB) was then started (regimen of 400 mg/ day, 5 mg/kg/day). The patient developed septic shock with intravascular disseminated coagulation and died after 6 days of antifungal treatment. Post-mortem examination documented multiple foci of fungal pneumonia, and cultures of lung yielded A. fl avus.
Materials and methods
We searched the MEDLINE database for Englishlanguage reports of IA in patients with liver diseases published up to November 2009. The key words used were ' Aspergillus infections ' , ' invasive aspergillosis ' , ' endstage liver disease ' , ' liver cirrhosis ' , ' hepatic failure ' , ' acute hepatitis ' . In addition, a secondary search was conducted by reviewing references cited in these papers and all the articles describing small or large case series of IA. We specifi cally selected cases classifi ed as having proven or probable IA based on the more recent Invasive Fungal Infections Group of the European Organization for the Research and Treatment of Cancer/Mycoses Study Group case defi nitions [8] . For the purpose of this study, cases occurring in liver transplant recipients, hematologic, or HIV patients were excluded. Clinical data included in the selected articles were reviewed, and a database was built. Disseminated Aspergillus infection was defi ned as an infection involving two or more organs not directly communicating.
Results

Patient demographic characteristics
Seventy-two patients fulfi lling criteria for probable or proven IA were included in the retrospective literature review [9 -39] . The demographics, risk factors, treatment, and outcome data of patients are summarized in Table 1 . Most patients were male (71.6%), and the median age was 49 years (range, 3 -78 years). Thirty-fi ve patients (48.6%) suffered from end-stage cirrhosis, 32 (44.4%) from acute hepatic failure, four (5.6%) from alcoholic hepatitis, and one (1.4%) from nonalcoholic steatohepatitis. A signifi cant percentage of patients (58.3%) had other risk factors for IA, most commonly involving the use of steroids, and less frequently the patients had diabetes and/ or COPD. 
Nature of infection and organ involvement
The species isolated included Aspergillus fumigatus ( n ϭ 17), and Aspergillus fl avus ( n ϭ 2) but no species was identifi ed in 53 cases (76.3%). Overall, almost all patients (94.4%) had lung involvement, 21 (29.2%) CNS involvement, 9 (12.5%) cardiac involvement, while 22 (30.5%) had disseminated infections.
Treatment and outcome
Thirty-fi ve patients (48.6%) received antifungal therapy, while the remaining received no treatment since the diagnosis was made postmortem. Table 2 , all the reported cases were divided in two study groups, i.e., 31 cases observed during the period 1973 -1999 and 41 cases observed in the period 2000 -2009. We created these two groups because of the increased availability in the last 10 years of antifungal drugs that are more effective against invasive mould infections and the increased ability to establish a correct diagnosis. Overall, a trend toward higher survival for patients diagnosed in the latter study group (mortality rate 87.1% vs 61%) was observed. Patients diagnosed after 2000 had a higher incidence of end-stage cirrhosis, and were more likely to be diagnosed during life and consequently being treated with an antifungal, and a localized infection in the lungs. Patients diagnosed during the period 1973 -1999 were more frequently affected by acute hepatic failure, and had more frequently a disseminated infection.
Discussion
IA has been traditionally regarded as an infection mainly occurring in patients with well established risk factors, such as neutropenia, hematologic malignancies, organ transplantation, or HIV [1] . Some recent studies have underscored the increasingly important role that Aspergillus species play in recipients of low doses of corticosteroids, patients with COPD, liver cirrhosis, transfusionassociated hemosiderosis, and diabetes mellitus [1, 4, 40] . Our review of the English literature confi rmed IA as a frequent undiagnosed complication of patients with acute hepatic failure or end-stage liver disease, with a mortality rate exceeding 70%.
Previously, patients with acute or advanced liver disease have been considered at specifi c risk for IA only as a result of immunosuppression following liver transplantation. However, liver disease alone predisposes to bacterial and fungal infections, as a result of a depression of both humoral and cell-mediated immunity [7] . Fiuza et al . described signifi cant defects in neutrophil migration and phagocytosis in patients with both Child-Pugh class B and C cirrhosis [41] , as well as the absence of the oxidative burst activity of neutrophils in this population [6] . Lombardo et al . reported signifi cant declines in peripheral CD4 lymphocyte subsets in all patients with cirrhosis. The severity of lymphocyte defi ciency paralleled the severity of cirrhosis, i.e., patients with Child-Pugh class A, B and C cirrhosis were found to have a median number of CD4 cells of 515/ μ l, 514/ μ l, and 307/ μ l, respectively, compared with 1329/ μ l in healthy control subjects [42] . Cirrhotic patients may also suffer additional problems due to their somewhat weakened immune system caused by corticosteroid therapy, transfusions of allogeneic blood products, hemodialysis, sepsis associated immunoparalysis, malnutrition, or poorly controlled glycemia [4] . Our review revealed that the 58.3% of all patients with liver disease and IA received concomitant steroids therapy.
Despite the presence of all these predisposing factors, patients with acute or advanced liver disease are not usually considered by physicians as a population at risk for IA, and this leads to a lack in diagnosis. This is confi rmed in our analysis, revealing how most cases of IA have been diagnosed post-mortem (52.8%). Thus most cases, as our patients, are initially considered to have a bacterial pneumonia, causing a delay in diagnosis and treatment of IA. This observation refl ects not only the unawareness of clinicians for the risk of IA in non-neutropenic patients, but also the diffi culty of making the clinical diagnosis. The pathogenesis of IA in non-neutropenic patients, e.g., those with steroid-associated immunosuppression, differs greatly to those who are neutropenic. While angioinvasive lesions are often widespread and death related to a high fungal burden in neutropenic animals, the pathogenesis in non-neutropenic, steroid-treated animals is driven by an adverse infl ammatory host response, with a low fungal burden in the lung parenchyma and less frequently, dissemination of infection [43] . Cultures of Aspergillus species from respiratory secretions have a low diagnostic sensitivity, and do not prove the presence of invasive infection. This was clearly demonstrated by Meersseman and coworkers, who found that bronchoalveolar lavage (BAL) cultures were positive in only 60% of cases of histologically proven pulmonary aspergillosis [37] . In addition, unlike in neutropenic patients, lung CT has limited value due to the absence of characteristic abnormalities, such as cavitation, air crescent sign, or halo sign. Moreover, Aspergillus infection may develop over preexisting atelectasis or in acute respiratory distress syndrome [4] .
The detection of galactomannan (GM) is a new valuable test for the diagnosis of IA. GM is a polysaccharide fungal cell wall component that is released during tissue invasion by Aspergillus hyphae and can be detected in body fl uids. Data on the performance of GM detection in serum are sparse in non-neutropenic patients, and suggest that serum GM is probably not a good marker for IA in this population [44] . As a matter of fact, GM serum results were negative in both patients described above. Instead, BAL GM was found to be very useful to diagnose pulmonary aspergillosis in ICU patients with proven infection (almost all cases were diagnosed by autopsy), with a sensitivity of 88% using a cutoff index of 0.5 [37] . However, although several sources of false positivity were frequently encountered in the ICU patients studied by Meersseman and colleagues, the specifi city was still above 85% [37] . All these data suggest that GM detection in the BAL fl uid can be considered as a useful test in non-neutropenic patients with evidence of pneumonia not responding to initial broad-spectrum antibiotic therapy. If the performance of a bronchoscopy is considered to be contraindicated, microbiological examination of sputum can be useful. A recent study showed that sputum was equivalent to BAL fl uid for GM detection [45] , at least in patients with hematologic malignancies (sensitivity and specifi city of sputum and BAL were 100% and 62.2% and 100%, and 83.3%, respectively). Our experience with two patients with hepatic failure and pulmonary aspergillosis confi rmed the usefulness of microbiological examination of sputum in that sputum samples yielded positive cultures and positive GM test results. However, available data suggests the use of a higher cut-off score (1 -1.2) for GM detection in sputum [45] , i.e., both of our patients had a value of 1.2 which would be considered positive. Although future studies are needed, this test could be considered an alternative option in those patients who are not able to undergo a bronchoscopy.
IA should be considered as a devastating infectious disease in patients with liver disease, carrying a mortality rate exceeding 70%. This high mortality may be related to the critical conditions of patients with end-stage liver disease or acute/fulminant hepatic failure, and to the absence of distinctive clinical features that frequently lead to a delay in diagnosis. Our review revealed a trend toward better survival rates in patients with IA diagnosed in the last decade. This fi nding is, in part, explained by the improvements in supportive care, but is also related to a greater awareness on the part of clinicians. In addition, improvements of diagnostic methods have led to a higher rate of the diagnosis of infection during life (66% vs 33% during the periods 2000 -2009 and 1973 -1999, respectively) . As a consequence, most patients reported in the last decade received an antifungal treatment (68.3% vs 22.6%) associated with an increased survival rate.
Treatment of IA is challenging in patients with severe liver disease. The drug of choice is voriconazole, but this drug is potentially hepatotoxic and is metabolized by cytochrome P-450 isoenzymes causing important drug interactions [46] . Thus, it should be used with caution in patients with severe hepatic failure. The alternative options are represented by lipid-formulations of AMB, which are less nephrotoxic than AMB deoxycholate. Patients with advanced cirrhosis and ascites frequently suffer from prerenal failure or more serious, a condition called hepatorenal syndrome [47] . Since lipid formulations reduce but do not ameliorate nephrotoxicity [48] , liposomal amphotericin B must be administered with caution, not exceeding the dosage of 3 mg/kg/day. More recent options are represented by antifungal agents of echinocandin class, including caspofungin, anidulafungin and micafungin, although clinical data on their use in cases of IA are limited. Caspofungin has been used in neutropenic adult and pediatric patients with IA, and favourable responses have been reported in 39 -50% of cases [49, 50] . Of importance, caspofungin and the other echinocandins have particularly favourable pharmacokinetic properties since they are not metabolized through the cytochrome P450 enzyme system, and can be safely administered to patients with moderate to severe liver failure.
In conclusion, IA is a potentially fatal complication in severe liver disease. Physicians should be aware in recognizing this potential fatal complication of patients with liver disease, in order to administer appropriate antifungal therapy and to reduce the associated mortality rate, which, despite the advance in diagnosis and treatment, is unacceptably high in this particular category of patients.
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